![Terrie Curran](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Terrie Curran
Director/Board Member at
ARCUTIS BIOTHERAPEUTICS, INC.
Net worth: 5 M $ as of 2026-03-30
Profile
Currently, Terrie Curran is Director at Roivant Sciences, Inc. and Independent Director at Arcutis Biotherapeutics, Inc. since 2020.
Formerly, served as President, Chief Executive Officer & Director at Phathom Pharmaceuticals, Inc. from 2019 to 2025; Independent Director at H.
Lundbeck A from 2014 to 2017; Director at BioNJ, Inc.; Independent Director at Myovant Sciences Ltd. from 2016 to 2023; President-Global Inflammation & Immunology at Celgene Corp.
from 2017 to 2019; SVP & GM-Global Women's Health at Merck & Co., Inc. from 2009 to 2013; and General Manager at Schering-Plough Corp.
from 2003 to 2007.
Education includes undergraduate degree from the University of Technology Sydney.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-22 | 389,860 ( 0.49% ) | 4 M $ | 2026-03-30 | |
| 2025-06-11 | 17,748 ( 0.01% ) | 418 143 $ | 2026-03-30 |
Terrie Curran active positions
| Companies | Position | Start |
|---|---|---|
| ARCUTIS BIOTHERAPEUTICS, INC. | Director/Board Member | 2020-11-01 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Director/Board Member | - |
Former positions of Terrie Curran
| Companies | Position | End |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Chief Executive Officer | 2025-03-30 |
| MYOVANT SCIENCES LTD. | Director/Board Member | 2023-03-09 |
| CELGENE | Corporate Officer/Principal | 2019-08-31 |
| H. LUNDBECK A/S | Director/Board Member | 2017-02-28 |
| MERCK & CO., INC. | Corporate Officer/Principal | 2013-03-31 |
Training of Terrie Curran
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
61
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
H. Lundbeck A/S
 H. Lundbeck A/S Pharmaceuticals: MajorHealth Technology Engages in the research, development, production and sale of pharmaceuticals for the treatment of brain diseases | Health Technology |
University of Technology Sydney
 University of Technology Sydney Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey | Commercial Services |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides women's health and prostate cancer solutions | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Arcutis Biotherapeutics, Inc.
 Arcutis Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an immunodermatology drug development company | Health Technology |
Phathom Pharmaceuticals, Inc.
 Phathom Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel treatments for gastrointestinal diseases and disorders | Health Technology |
- Stock Market
- Insiders
- Terrie Curran
